Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations

Proteolysis targeting chimeric molecule ARV 825 causes ubiquitination of bromodomains resulting in their efficient degradation by proteasome activity. Bromodomain degradation down-regulates MYC transcription contributing to growth inhibition of various human cancers. We examined the therapeutic pote...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Su Lin, Damnernsawad, Alisa, Shyamsunder, Pavithra, Chng, Wee Joo, Han, Bing Chen, Xu, Liang, Pan, Jian, Pravin, Dakle Pushkar, Alkan, Serhan, Tyner, Jeffrey W., Koeffler, H. Phillip
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545861/
https://www.ncbi.nlm.nih.gov/pubmed/30606790
http://dx.doi.org/10.3324/haematol.2018.201483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545861/
https://www.ncbi.nlm.nih.gov/pubmed/30606790
http://dx.doi.org/10.3324/haematol.2018.201483

Ejemplares similares